09/ 422,451

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1202txn
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1	Feb 2	Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Dec 17	Expanded CAplus Coverage of US, Japanese, WIPO, EPO, and German patents
NEWS	3	Dec 13	INFOR no longer available
NEWS	4	Jan 18	ESBIOBASE - NEW FREE DISPLAY FORMATS, TRIAL FORMAT ENHANCED
NEWS	5	Feb 1	Addition of Machine-Translated Abstracts to CAplus
NEWS	6	Feb 2	STEREO BOND SEARCH PROBLEM FIXED WITH STN EXPRESS 5.0C

NEWS EXPRESS	FREE UPGRADE 5.0C NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:11:18 ON 09 FEB 2000

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 09:11:26 ON 09 FEB 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 8 FEB 2000 HIGHEST RN 255065-85-1
DICTIONARY FILE UPDATES: 8 FEB 2000 HIGHEST RN 255065-85-1

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 13, 1999

Please note that search-term pricing does apply when

conducting SmartSELECT searches.

=>
Uploading 422451.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 09:11:54 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 4 TO ITERATE
100.0% PROCESSED 4 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 4 TO 200
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> s l1 ful

FULL SEARCH INITIATED 09:12:03 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 159 TO ITERATE
100.0% PROCESSED 159 ITERATIONS 72 ANSWERS
SEARCH TIME: 00.00.01

L3 72 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.30	126.45

FILE 'CAPLUS' ENTERED AT 09:12:09 ON 09 FEB 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1967 - 9 Feb 2000 VOL 132 ISS 7
FILE LAST UPDATED: 8 Feb 2000 (20000208/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGlstRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

=> s l3

L4 10 L3

=> d l4 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 10 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1999:764041 CAPLUS
DOCUMENT NUMBER: 132:22971
TITLE: Preparation of oxopyrido- and -pyrimidopyrimidines as cellular proliferation inhibitors
INVENTOR(S): Dobrusin, Ellen Myra; Hamby, James Marino; Kramer, James Bernard; Schroeder, Mel Conrad; Showalter, Howard Daniel Hollis; Toogood, Peter; Trumpp-Kallmeyer, Susanne A.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9961444	A2	19991202	WO 1999-US10187	19990510
W: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1998-86708 19980526
US 1999-126158 19990325
OTHER SOURCE(S): MARPAT 132:22971

GI



I

AB Title compds. [I; G = NR2 or CHR2; R = NHR1 or SO0-2R1; R1,R2 = H, (cyclo)alkyl, (un)substituted PH, -pyridyl, etc.; R3 = groups cited for R1, OH, alkoxy(carbonyl), etc.; R4 = H; R3R4 = bond; R8,R9 = H, halo, NH2, alkoxycarbonyl, etc.; X = O, S, (alkyl)imino, etc.; Z =N or CH] were prepd. as cyclin-dependant and tyrosine kinase inhibitors. Thus, 5-aminomethyl-4-cyclopentylamino-2-methylthiopyrimidine (prepn. given) was cyclocondensed with 1,1'-carbonyldiimidazole and the oxidized product aminated by 4-(MeO)C6H4NH2 to give I [G = cyclopentylimino, R = 4-(MeO)C6H4NH, R3 = R4 = R8 = R9 = H, X = O]. Data for biol. activity of I were given.

IT **251370-13-5P 251370-14-6P 251370-15-7P**
251370-16-8P 251370-17-9P 251370-18-0P
251370-19-1P 251370-20-4P 251370-21-5P
251370-22-6P 251370-23-7P 251370-24-8P
251370-25-9P 251370-26-0P 251370-27-1P
251370-28-2P 251370-29-3P 251370-30-6P
251370-31-7P 251370-32-8P 251370-33-9P
251370-66-8P 251370-67-9P 251370-68-0P
251371-07-0P 251371-08-1P 251371-09-2P
251371-10-5P 251371-11-6P 251371-12-7P
251371-13-8P 251371-14-9P 251371-17-2P
251371-18-3P 251371-19-4P 251371-20-7P
251371-21-8P 251371-22-9P 251371-89-8P
251371-90-1P 251371-91-2P 251371-92-3P
251371-93-4P
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation)

RN 251370-13-5 CAPLUS

CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-14-6 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(2-chloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-15-7 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(2,6-dichloro-3,5-dimethoxyphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-16-8 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxy-2-methylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-17-9 CAPLUS
CN Piperazine, 1-(aminoacetyl)-4-[4-[[6-(3,5-dimethoxy-2,6-dimethylphenyl)-8-ethyl-5,6,7,8-tetrahydro-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]phenyl]- (9CI) (CA INDEX NAME)



RN 251370-18-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
7-[[4-[2-(diethylamino)ethoxy]phenyl]a
mino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-19-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-
[2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA
INDEX NAME)



RN 251370-20-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-
[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA
INDEX NAME)



RN 251370-21-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
7-[[4-[2-(diethylamino)ethoxy]phenyl]a
mino]-3-(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA
INDEX NAME)



RN 251370-22-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
7-[[4-[2-(diethylamino)ethoxy]phenyl]a
mino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI)
(CA
INDEX NAME)



RN 251370-23-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-
(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-24-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
3-(2-chloro-3,5-dimethoxyphenyl)-7-[[4-
(diethylamino)butyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-25-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-7-
[[4-(diethylamino)butyl]amino]-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-26-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-
(3,5-dimethoxy-2-methylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-27-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



RN 251370-28-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-29-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2-chloro-3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-30-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-
ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-31-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
3-(3,5-dimethoxy-2,6-dimethylphenyl)-1-
ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-32-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxy-2-methylphenyl)-1-
ethyl-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-33-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 1-cyclopentyl-3-(2,6-dichloro-3,5-dimethoxyphenyl)-3,4-dihydro-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251370-66-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-(diethylamino)butyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)



RN 251370-67-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl- (9CI) (CA INDEX NAME)



RN 251370-68-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-(3,5-dimethoxyphenyl)-1-ethyl-7-(4-pyridinylamino)- (9CI) (CA INDEX NAME)



RN 251371-07-0 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-08-1 CAPLUS
CN Benzamide, 3-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-N-[3-(dimethylamino)propyl]-(9CI)
(CA INDEX NAME)



RN 251371-09-2 CAPLUS
CN Benzamide, 3-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]-N-[3-(dimethylamino)propyl]- (9CI) (CA INDEX NAME)



RN 251371-10-5 CAPLUS
CN Benzoic acid, 3-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-11-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichlorophenyl)-7-[[4-[2-(ethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA INDEX NAME)



RN 251371-12-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one,
3-(2,6-dichloro-3-hydroxyphenyl)-7-[[4-
[2-(ethylamino)ethoxy]phenyl]amino]-3,4-dihydro-1-methyl- (9CI) (CA
INDEX
NAME)



RN 251371-13-8 CAPLUS
CN Benzamide, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-
oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-14-9 CAPLUS
CN Benzamide, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-
methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-17-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-1-methyl-7-[[4-(4-morpholinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-18-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(2,6-dichloro-3-hydroxyphenyl)-3,4-dihydro-7-[[3-(hydroxymethyl)phenyl]amino]-1-methyl- (9CI) (CA INDEX NAME)



RN 251371-19-4 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-20-7 CAPLUS
CN Benzenebutanoic acid, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-21-8 CAPLUS
CN Benzaldehyde, 4-[[6-(2,6-dichlorophenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-22-9 CAPLUS
CN Benzaldehyde, 4-[[6-(2,6-dichloro-3-hydroxyphenyl)-5,6,7,8-tetrahydro-8-methyl-7-oxopyrimido[4,5-d]pyrimidin-2-yl]amino]- (9CI) (CA INDEX NAME)



RN 251371-89-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[2-[(4-pyridinylmethyl)amino]ethyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-90-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[3-(4-methyl-1-piperazinyl)propyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-91-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[4-(4-methyl-1-piperazinyl)butyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-92-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro-7-[[5-(4-methyl-1-piperazinyl)pentyl]amino]- (9CI) (CA INDEX NAME)



RN 251371-93-4 CAPLUS
CN Pyrimido[4,5-d]pyrimidin-2(1H)-one, 7-[[3-(diethylamino)propyl]amino]-3-(3,5-dimethoxyphenyl)-1-ethyl-3,4-dihydro- (9CI) (CA INDEX NAME)



IT **251372-02-8P 251372-03-9P 251372-04-0P 251372-05-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation)
RN 251372-02-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1-(1-methylethyl)-7-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-3-(2-propenyl)- (9CI) (CA INDEX NAME)



RN 251372-03-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)-7-[[4-(4-methyl-1-piperazinyl)phenyl]amino]- (9CI) (CA INDEX NAME)



RN 251372-04-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-1-(1-methylethyl)-3-(2-propenyl)- (9CI)
(CA INDEX NAME)



RN 251372-05-1 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[[4-[2-(diethylamino)ethoxy]phenyl]amino]-3-[(4-methoxyphenyl)methyl]-1-(1-methylethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1995:334056 CAPLUS
DOCUMENT NUMBER: 122:239631
TITLE: Purines, pyrimidines and condensed systems based on them. 12. 1,3-Dimethylpyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione: the first case of regioselective amination of condensed pyrimidines at position 2
AUTHOR(S): Gulevskaya, A. V.; Pozharsky, A. F.; Shorshnev, S. V.; Zheltushkina, E. A.
CORPORATE SOURCE: Rostov. Gos. Univ., Rostov-on-Don, 344006, Russia
SOURCE: Khim. Geterotsikl. Soedin. (1994), (9), 1249-52
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI



AB Amination of the title compd. in the presence of an oxidizing agent gave 7-amino derivs. (I; NR1R2 = NH2, NHMe, NHEt, NHCMe3, piperidino, morpholino); in the case of Me2NH the 4-substituted deriv. (II) was also formed. Successive hydrolysis of I (NR1R2 = piperidino) in alk. and acidic medium gave 4-(methylamino)-2-piperidinopyrimidine (III).
IT **94839-44-8P 94839-45-9P 162147-58-2P 162147-59-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 94839-44-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 94839-45-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1,3-dimethyl-7-(methylamino)- (9CI) (CA INDEX NAME)



RN 162147-58-2 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-(ethylamino)-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 162147-59-3 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-[(1,1-dimethylethyl)amino]-1,3-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1994:134411 CAPLUS
DOCUMENT NUMBER: 120:134411
TITLE: Reactions of uracils. 21. Zwitterionic heteropolycyclic uracils by a novel three-component reaction: iminophosphorane, isocyanate, heteroarene
AUTHOR(S): Wamhoff, Heinrich; Schmidt, Andreas
CORPORATE SOURCE: Inst. Org. Chem. Biochem., Univ. Bonn, Bonn, D-53121, Germany
SOURCE: J. Org. Chem. (1993), 58(25), 6976-84
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:134411
GI



AB The novel three-component reaction of (uracil-6-ylimino)phosphorane I, isocyanate, and (substituted) pyridines gives, in a one-pot procedure, a variety of new pyrido[1',2':3,4]pyrimido[4,5-d]pyrimidines, e.g., II (R = aryl, Me2CH, tosyl, allyl). The zwitterionic ground state of these new ring systems is established by solvatochromism, Hammett correlations, NMR, and X-ray anal. Replacement of the pyridine by isoquinoline and

phthalazine gives access to the novel ring systems pyrimido[4',5':4,5]pyrimido[6,1-a]isoquinoline and -phthalazine, which are formed as dihydro derivs. [III; X = CH, N (15); R = aryl] or as zwitterions, depending on the reaction conditions. Oxidative cleavage of the phthalazine 15 in nitrobenzene affords the (cyanophenyl)pyrimido[4,5-d]pyrimidines.

IT **152897-89-7P 152897-90-0P 152897-91-1P 152897-92-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and oxidn. or thermal cleavage of)

RN 152897-89-7 CAPLUS
CN Benzonitrile, 2-[5,6,7,8-tetrahydro-6,8-dimethyl-5,7-dioxo-2-(phenylamino)pyrimido[4,5-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 152897-90-0 CAPLUS
CN Benzonitrile, 2-[2-[(4-chlorophenyl)amino]-5,6,7,8-tetrahydro-6,8-dimethyl-5,7-dioxopyrimido[4,5-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 152897-91-1 CAPLUS
CN Benzonitrile, 2-[5,6,7,8-tetrahydro-6,8-dimethyl-5,7-dioxo-2-[[3-(trifluoromethyl)phenyl]amino]pyrimido[4,5-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



RN 152897-92-2 CAPLUS
CN Benzonitrile,
2-[5,6,7,8-tetrahydro-6,8-dimethyl-2-[(4-methylphenyl)amino]-
5,7-dioxopyrimido[4,5-d]pyrimidin-4-yl]- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1992:531144 CAPLUS
DOCUMENT NUMBER: 117:131144
TITLE: Cyclization reactions of chloro-substituted 2-azoniaallene salts with bifunctional nucleophiles
AUTHOR(S): Hamed, Atef
CORPORATE SOURCE: Fac. Sci., Menoufia Univ., Shebin El-Koom, Egypt
SOURCE: Synthesis (1992), (6), 591-5
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II



III



IV



V

AB Multifunctional electrophilic chloro-substituted 2-azoniaallene salts react with bifunctional nucleophiles to furnish heterocycles. Thus, PhCCl:N+:CClPh SbCl6- reacts with pyrimidinedione I to give pyrimidopyrimidinedione salt II. Pyrimido-1,3-oxazin-1-ium salts, e.g., III, representing a new ring system, triazinium salts, e.g., IV, and a triazolium salt (V) are also obtained.

IT **143249-47-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 143249-47-2 CAPLUS

CN Antimonate(1-), hexachloro-, (OC-6-11)-, hydrogen, compd. with 7-(dimethylamino)-1,3-dimethylpyrimido[4,5-d]pyrimidine-2,4,5(1H,3H,6H)-trione (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 143249-46-1
CMF C10 H13 N5 O3



CM 2

CRN 16941-91-6
CMF Cl6 Sb . H
CCI CCS
CDES 7:OC-6-11



L4 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1990:514913 CAPLUS
DOCUMENT NUMBER: 113:114913
TITLE: Pyrimidines. 63. Novel ring transformations of 5-cyanouracils into 2-thiocytosines, 2,4-diaminopyrimidines, and pyrimido[4,5-d]pyrimidines by the reaction with thioureas and guanidines
AUTHOR(S): Hirota, Kosaku; Sajiki, Hironao; Kitade, Yukio; Maki, Yoshifumi
CORPORATE SOURCE: Gifu Pharm. Univ., Gifu, 502, Japan
SOURCE: J. Chem. Soc., Perkin Trans. 1 (1990), (1), 123-8
CODEN: JCPRB4; ISSN: 0300-922X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 113:114913
GI



I

II



III

AB 1,3-Disubstituted 5-cyanouracils react with thioureas and guanidines to give the 5-carbamoyl-2-thiocytosines I (R = H, Me, Bu, Ph; R1 = Me, cyclohexyl) and 2,4-diamino-5-carbamoylpyrimidines II (R = Ph, Me; R1 = Me, H), resp. On the other hand, 1-aryl-5-cyanouracils react with thioureas to give 7-aminopyrimido [4,5-d]pyrimidine-2,4-diones III (R = H, Me; R2 H, OMe).

IT **94839-44-8P 101989-67-7P 128836-42-0P 129088-65-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 94839-44-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 101989-67-7 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-3-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 128836-42-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-1-(4-methoxyphenyl)-3-methyl- (9CI) (CA INDEX NAME)



RN 129088-65-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 3-methyl-7-(methylamino)-1-phenyl- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1987:162576 CAPLUS
DOCUMENT NUMBER: 106:162576
TITLE: Preparation and formulations of pyrimido[4,5-d]pyrimidine derivatives as antiallergics
INVENTOR(S): Kitamura, Norihiko; Onishi, Akimoto
PATENT ASSIGNEE(S): Nippon Zoki Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61249988	A2	19861107	JP 1985-90357	19850425
JP 06013518	B4	19940223		

GI



I



II

AB The title compds. (I; R1, R2 = alkyl; R3 = NH2, alkylamino; R4 = H, alkyl, Ph, NH2) are prepd. from uracil derivs. (I; R1 and R2 = alkyl; Y = NH2, halo, dialkylaminomethyleneamino) and H2NZ (Z = C:XR4; X = O, NH; R4 = H, alkyl, Ph, NH2). Thus, 6-amino-5-cyano-1,3-dimethyluracil was cyclized with formamide to give 5-amino-1,3-dimethylpyrimido[4,5-d]pyrimidine-2,4-dione (III). III at 100 mg/kg in rats inhibited allergic reactions. A tablet contained III 10, lactose 130, starch 40, and Mg stearate 10 mg.

IT **56007-62-6P**
RL: PREP (Preparation)
(prepn. of, as antiallergic)

RN 56007-62-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 5,7-diamino-1,3-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1986:186439 CAPLUS
DOCUMENT NUMBER: 104:186439
TITLE: Pyrimidopyrimidinedione derivatives and their use as anti-allergic agents

INVENTOR(S): Kitamura, Norihiko; Ohnishi, Akimoto
PATENT ASSIGNEE(S): Nippon Zoki Pharmaceutical Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 51 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 163599	A2	19851204	EP 1985-810182	19850424
EP 163599	A3	19870225		
EP 163599	B1	19900321		
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
JP 60226882	A2	19851112	JP 1984-83557	19840424
JP 05059118	B4	19930830		
AT 51231	E	19900415	AT 1985-810182	19850424
US 4886807	A	19891212	US 1988-277447	19881129
PRIORITY APPLN. INFO.:			JP 1984-83557	19840424
			EP 1985-810182	19850424
			US 1985-726618	19850424

GI



I

AB The title compds. (I; R1 = alkyl; R2 = alkyl, Ph; R3 = H, alkyl, alkylamino; R4 = H, (halo)alkyl, Ph, amino, alkylamino) were prepd. Thus,
6-amino-1,3-dimethyluracil underwent Vilsmeier reaction with HCONMe2 to give 95% 5-[(dimethylamino)methylene]-5,6-dihydro-6-imino-1,3-dimethyluracil which was refluxed with thiourea in EtOH contg. NaOEt to give 52% I (R1 = R2 = Me, R3 = H, R4 = NH2) (II). In rats 20 mg II/kg orally gave 53.3% inhibition of passive cutaneous anaphylaxis reaction compared to 67.3% for theophylline.

IT **56007-62-6P 94839-44-8P 94839-45-9P 101989-67-7P 101989-73-5P 101989-74-6P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as allergy inhibitor)

RN 56007-62-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 5,7-diamino-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 94839-44-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 94839-45-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1,3-dimethyl-7-(methylamino)- (9CI) (CA INDEX NAME)



RN 101989-67-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-3-methyl-1-phenyl- (9CI) (CA INDEX NAME)



RN 101989-73-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-1,3-diethyl- (9CI) (CA INDEX NAME)



RN 101989-74-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-3-methyl-1-(2-methylpropyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2000 ACS
ACCESSION NUMBER: 1985:95601 CAPLUS
DOCUMENT NUMBER: 102:95601
TITLE: A facile synthesis of 7-substituted pyrimido[4,5-d]pyrimidine-2,4-diones
AUTHOR(S): Hirota, Kosaku; Kitade, Yukio; Sajiki, Hironao; Maki, Yoshifumi
CORPORATE SOURCE: Gifu Pharm. Univ., Gifu, 502, Japan
SOURCE: Synthesis (1984), (7), 589-90
CODEN: SYNTBF; ISSN: 0039-7881
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I



II

AB Cyclization of uracil I with RC(X)NH2 (R = H, Me, CF3, Ph, H2N, MeNH; X = O, S, NH) gave 52-92% 7 title compds. II.

IT **94839-44-8P 94839-45-9P**
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and spectra of)

RN 94839-44-8 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 94839-45-9 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1,3-dimethyl-7-(methylamino)-(9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1981:156846 CAPLUS

DOCUMENT NUMBER: 94:156846

TITLE: Phosgeniminium salts. Part 28. Annelation of 5 or 6 membered heterocycles to uracil derivatives via phosgeniminium salt condensation

AUTHOR(S): Kokel, B.; Lespagnol, C.; Viehe, H. G.

CORPORATE SOURCE: Lab. Chim. Org., Univ. Louvain, Louvain-la-Neuve, B-1348, Belg.

SOURCE: Bull. Soc. Chim. Belg. (1980), 89(8), 651-7
CODEN: BSCBAG; ISSN: 0037-9646

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I



II



III



IV

AB Reaction of the uracil I (R = NH2, R1 = H) with Me2N+:CCl2Cl- gave I (R = NH2, R1 = CCl:N+Me2Cl-) which reacted with nucleophiles to give I [R = NH2, R1 = CXNMe2, X = O, NPh, NNH2, NCN, C(CN)2]. The latter 2 compds. were hydrolyzed to II (X1 = N, CCN). Reaction of, I (R = OH, R1 = H) with Me2N+:CCl2Cl- gave III which also reacted with nucleophiles to give I (R = OH, R1 = CXNMe2, X = NH, NPh, NOH). The latter compd. was cyclized by heating to IV.

IT **77008-19-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 77008-19-6 CAPLUS

CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 7-amino-5-(dimethylamino)-1,3-dimethyl- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2000 ACS

ACCESSION NUMBER: 1976:74208 CAPLUS

DOCUMENT NUMBER: 84:74208

TITLE: Cycloacylation of enamines. III. Synthesis and reactions of pyrimido[4,5-d]pyrimidines

AUTHOR(S): Grohe, Klaus; Heitzer, Helmut

CORPORATE SOURCE: Zent. Forsch., Bayer A.-G., Leverkusen, Ger.

SOURCE: Justus Liebigs Ann. Chem. (1975), Volume Date 1974, (12), 2066-73
CODEN: JLACBF

DOCUMENT TYPE: Journal
LANGUAGE: German
GI For diagram(s), see printed CA Issue.
AB Reaction of the 4-aminouracils I with Cl3CN:CCl2, Cl3CCCl:NCCl2CCl3, PhCCl2N:CCl2, or Cl3CCCl2NCO gave by cycloacylation the pyrimidopyrimidines II (R = Me, CH2CH2Ph, CH2:CHCH2, or H; R1 = Me, R2 = CCl3, R3 = Cl), II (R = R1 = Me, R2 = Cl, R3 = Ph) and II (R = R1 = Me, R2 = Ph, R3 = Cl), or II (R = R1 = Me, R2 = CCl3, R3 = OH), resp. Some nucleophilic substitution reactions of III were reported.
IT **56007-74-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction with nitrofuraldehyde)
RN 56007-74-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4,7(1H,3H,6H)-trione, 5-(ethylamino)-1,3-dimethyl-, 7-hydrazone (9CI) (CA INDEX NAME)



IT **56007-61-5P 56007-62-6P 56007-63-7P**
56007-64-8P 56007-65-9P 56007-66-0P
56007-71-7P 56007-75-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 56007-61-5 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 5,7-bis(ethylamino)-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 56007-62-6 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 5,7-diamino-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 56007-63-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1,3-dimethyl-5,7-bis[(1-methylethyl)amino]- (9CI) (CA INDEX NAME)



RN 56007-64-8 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 5,7-bis(butylamino)-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 56007-65-9 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 5,7-bis(dodecylamino)-1,3-dimethyl- (9CI) (CA INDEX NAME)



RN 56007-66-0 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 1,3-dimethyl-5,7-bis[(phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 56007-71-7 CAPLUS
CN Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-dione, 5,7-bis(ethylamino)-1,3-di-2-propenyl- (9CI) (CA INDEX NAME)



RN 56007-75-1 CAPLUS
CN 2-Furancarboxaldehyde, 5-nitro-, [4-(ethylamino)-5,6,7,8-tetrahydro-6,8-dimethyl-5,7-dioxopyrimido[4,5-d]pyrimidin-2-yl]hydrazone (9CI) (CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 09:11:18 ON 09 FEB 2000)

FILE 'REGISTRY' ENTERED AT 09:11:26 ON 09 FEB 2000
L1 STRUCTURE UPLOADED

```
L2             2 S L1
L3            72 S L1 FUL

     FILE 'CAPLUS' ENTERED AT 09:12:09 ON 09 FEB 2000
L4            10 S L3

=> log y

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    40.22     166.67

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -5.57      -5.57

STN INTERNATIONAL LOGOFF AT 09:13:24 ON 09 FEB 2000
```